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Abstract
We have previously reported a world-first phase I clinical trial to treat HCV patients using monocyte-derived dendritic cells
(Mo-DC) loaded with HCV-specific lipopeptides. While the brief treatment proved to be safe, it failed to reduce the viral load
and induced only transient cell-mediated immune responses, measured by IFNc ELIspot. Here we reanalysed the PBMC
samples from this trial to further elucidate the immunological events associated with the Mo-DC therapy. We found that
HCV-specific single- and multi-cytokine secreting T cells were induced by the Mo-DC immunotherapy in some patients,
although at irregular intervals and not consistently directed to the same HCV antigen. Despite the vaccination, the
responses were generally poor in quality and comprised of primarily single-cytokine secreting cells. The frequency of
FOXP3+ regulatory T cells (Treg) fluctuated following DC infusion and eventually dropped to below baseline by week 12, an
interesting trend suggesting that the vaccination may have resulted in a more subtle outcome than was initially apparent.
Our data suggested that Mo-DC therapy induced complex immune responses in vivo that may or may not lead to clinical
benefit.
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Introduction
Hepatitis C virus (HCV) persistently infects ,3% of the world’s
population, leading to cirrhosis, cancer and liver failure. Despite
the burden of this disease, no vaccine is available and treatment
options still remain limited, particularly in those who fail to
respond to the current standard of care. We have previously
completed a Phase I clinical trial to treat HCV patients using
dendritic cell therapy [1]. In this trial, Mo-DC from HLA-A2
positive, HCV genotype 1 infected patients, who had previously
failed interferon-based therapy, were generated ex vivo [1]. The
Mo-DC were pulsed with six lipopeptides comprised of HLA-A2-
restricted HCV-specific cytotoxic T lymphocyte (CTL) epitopes,
each linked to a universal Th epitope, and to the TLR2 agonist
Pam2Cys [2]. The cells were exposed to prostaglandin E2 then
infused into the patient by the intravenous and/or intradermal
routes. Patients received 1, 2 or 3 infusions at 2 weekly intervals.
While all patients tolerated the injections well, there were no dose-
or time-dependent reductions in the HCV viral load following the
DC infusions. Analysis of the T cell response, determined by the
secretion of IFNc and measured by ELIspot, showed that only
relatively weak anti-HCV immunity was induced, as only transient
and sporadic cell mediated responses were detected that appeared
to have no apparent correlation with the dose or the timing of the
DC infusions.
To our knowledge this is the first and only trial of DC therapy in
HCV patients. Induction of HCV-specific T cells was measured as
IFNc-producing cells by ELIspot assay as this was considered to be
the gold standard for immunological assessment in the clinical
setting. However, the induction of multi-functional effector T cells,
which produce multiple cytokines simultaneously, are believed to be
critical for immune defence against pathogens [3] and current
opinion is that this should be borne in mind for vaccine
development [4]. Consequently, to assess the potential of Mo-DC
therapy it is critical to determine if multi-functional effector cells
were induced.
The aim of this study was to re-examine PBMC from patients in
this trial for evidence of multi-functional effector T cells and/or
any change in the frequency of regulatory T cells that might help
explain the low levels of induced immune responses.
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Materials and Methods
Patients and cells
A total of 6 patients were treated in the trial as described
previously [1]. PBMC analysed here were sampled before and after
Mo-DC infusion and cryo-preserved. Cryo-preserved PBMC from
5 healthy donors (Australian Red Cross Blood Service) served as
controls. The study was approved by the Alfred Hospital Human
Research Ethics Committee and the Victorian Department of
Human Services Human Research Ethics Committee. Written
informed consent was obtained from each patient and volunteer.
Antigens
The HCV peptide array for genotype 1a, which contains 18-mer
peptides overlapping by 11aa, was provided by BEI Resources,
ATCC. Peptide pools (pp) corresponding to the HCV core, E1/E2,
P7/NS2, NS3, NS4A/4B, NS5A and NS5B proteins were prepared
as working stocks of 100 mg/ml in DMSO/RPMI and the final
concentration in culture was 2 mg/ml. The 6 HCV CTL epitopes
contained in the cellular vaccine (HCV core 35 YLLPRRGPRL,
core 132 DLMGYIPLV, core 177 FLLALLSCLTV, NS3 1406
KLVALGINAV, NS4B 1807 LLFNILGGWV and NS4B 1851
ILAGYGAGV) were pooled and the final concentration for each in
Figure 1. Gating strategy and example of ICS data. (A) Lymphocytes were gated based on FSC and SSC, followed by a CD3+ViViD2 viable T cell
gate. (B) Example of data from PT#3, depicting typical positive (66CTL, core antigen) and negative (E1E2 antigen) responses following DC infusion
compared to baseline. (C) These plots are derived from the same data as the core antigen response at week 2 (W2), depicting the cellular source of
the cytokines. The 1st plot (left) shows cytokine positive cells (red) within viable CD3 T cells (grey), the 2nd plot shows the position of the CD4+ and
CD8+ T cell gates, and the 3rd and 4th plots depict the cytokine staining profiles of CD4+ T cells and CD8+ T cells respectively.
doi:10.1371/journal.pone.0039368.g001
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Figure 2. Cytokine positive responses - a complete dataset from all patients. (A) Cytokine producer frequency (%, gating on viable CD3+ T
cells) at baseline and different time points thereafter. The numbers on the x-axis (1, 2, 3, 4, 5 and 6) are the patient ID. Abbreviations: BL = Base Line;
PI-2 = Prior to 2nd Infusion; PI-3 = Prior to 3rd Infusion, W=Week post final infusion. (B) The normalised MFI, corresponding to the responses detected
DC Immunotherapy in HCV Infection
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the culture, and for P25, the universal Th epitope, was 2 mg/ml.
Positive controls comprised 2 mg/ml CEF peptide pool (containing
major CTL epitopes of human cytomegalovirus, Epstein–Barr virus
and influenza A virus [5]).
Antibodies
FOXP3 antibody, its isotype control antibody and staining
buffers were purchased from eBiosciences (San Diego, US), and all
the other antibodies and isotype controls were purchased from BD
Biosciences (New Jersey, US)
Intracellular staining
ICS was performed essentially as described previously [6,7]. In
brief, cryopreserved PBMC were thawed into warm RPMI-1640
supplemented with 10 U/ml DNase (Sigma-Aldrich, Castle Hill,
NSW, Australia), and washed 2 times in this medium. The cells
were then resuspended (56106 PBMC/mL) in complete medium
containing RPMI-1640, 2 mM L-glutamine, 100 IU/mL penicil-
lin-streptomycin (Invitrogen, Mount Waverley, VIC, Australia)
and 10% FBS (Thermo Fisher Scientific, Scoresby, Victoria,
Australia) and rested overnight (,16 h) at 37uC with 5% CO2.
The cells were washed and resuspended in a 96-well U-bottom
plate in complete medium. Test or control antigens were added to
a final concentration of 2 mg/mL and the cultures incubated for
6 hours, with BrefeldinA and Monensin (eBiosciences) supple-
mentation for the final 5 hours. After stimulation, the cells were
first stained with ViViD (Invitrogen) to discriminate dead cells,
followed by surface staining for CD3 and CD4 and then
intracellular staining of IFN-c, TNFa and IL-2. A small number
of cells were used immediately after resting (without antigen
stimulation) for detection of FOXP3 as we described previously
[8]. Flow cytometry was performed using BD SLRII, and data
were analysed using FlowJo online software. Data are expressed as
the percentage of cytokine producing cells within the gated viable
T cells, background-subtracted using the no antigen control of the
same PBMC sample. When the mean fluorescent intensity (MFI)
of the cytokine producing cells was examined, this value was
normalised to the cytokine negative cells within the same plot to
minimise background fluorescence variation between samples.
Statistical methods
Differences among the repeated measurements of FOXP3+
were evaluated using the Skillings-Mack test, which is the non-
parametric equivalent of the one-way repeated measures AN-
OVA, and Wilcoxon signed-ranks tests for paired data with
Bonferroni adjustment for multiple comparisons. P-values ,0.05
were considered statistically significant. The correlation between
the frequencies of FOXP3+ Treg and CEF-specific IFNc/TNFa
double producing T cells was calculated using a linear regression
model (least squares fitting).
Results and Discussion
1. Detection of multi-functional T cells by intracellular
cytokine staining
The Mo-DC dose each patient received and the viral load at
various time points before and after the cell infusion were
described previously [1]. In brief, our trial had 6 patients only, and
as a dose escalation trial each patient received a different DC
infusion dose and/or route (Table 1). We analysed PBMC from
each patient in an independent experiment, in which all samples
(various time points) from this patient were assayed in a single 96-
well plate (to ensure that different PBMC samples from the same
patient were compared directly) and the positive controls (to
simply confirm the reactivity of the reagents) were assayed in a
second plate. In addition, each assay also included a healthy donor
PBMC sample as a negative control (to rule out false positives from
the reagents). We gated on viable CD3+ T cells, with the help of
ViViD dye (Invitrogen) [6] (Fig. 1A) and defined the cytokine
positive cells with a generous clearance from the negative
population (Fig. 1B). We then plotted the frequency of T cells
according to their functional status, viz. TNFa or IFNc single
producer and TNFa/IFNc double producer, as illustrated in
Fig. 2A. To emphasize antigen-specific cytokine production, all
data used to generate this figure were background subtracted using
the no antigen control (the raw data without background
subtraction are provided in Table S1).
We found that single and/or double positive T cells were
detected in every patient, although the timing and the exact HCV
protein specificity varied. The quality of the responses was poor,
and mostly comprised cells which secreted a single cytokine. This
is in sharp contrast to the in vitro positive control CEF, which
induced strong IFNc/TNFa double positive responses, sometimes
in the absence of single positive responses (Figure S1). Within the
single cytokine category, TNFa producers showed a higher
frequency compared to IFNc producers, and in some patients
(such as PT#2) these cells showed an increasing trend post
vaccination (Fig. 2A). Although few in number, on a per cell basis
the dual positive cells produced higher levels of cytokines, reflected
by an overall higher MFI, in particular in the TNFa PE channel
(Fig. 2B). All MFI used in this study were normalised as outlined in
the method section. These data are consistent with the notion that
multi-functional T cells are superior to single functional T cells
[3,9]. These data also highlight the fact that induction of multi-
functional T cells is highly desirable for HCV vaccine design.
Unfortunately, apart from some isolated examples, for instance the
increase in MFI post vaccination in PT#4 and PT#5 (plotted
individually in Fig. 2C), we did not observe an overt improvement
in T cell quality by the Mo-DC therapy.
in (A). (C) T cell quality in PT#4 and PT#5, depicted by the normalised MFI of cytokine positive responses. (D) The frequency (%) and normalised MFI
over time in PT#3. (E) The dose and timing of DC infusion each patient received and the timing of sample collection. (F) Contribution of CD4 and
CD8 T cells (please note the differences in scale) to the cytokine positive responses in PT#3.
doi:10.1371/journal.pone.0039368.g002
Table 1. Summary of the dose escalation trial. 1 dose
unit = 16107 DC.
Patient ID 1st infusion 2nd infusion 3rd infusion
# 1 !
# 2 ! !
# 3 ! !! !!!!!
# 4 ! !!!!!
# 5 !! !! !!
# 6
(!= 1 dose unit infused via i.v route and = 1 dose unit infused via i.d route).
(Adapted from Gowans et al. (2010) J Hepatol; 53:599).
doi:10.1371/journal.pone.0039368.t001
DC Immunotherapy in HCV Infection
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Upon further inspection we noted an increase in T cell
responses post vaccination in PT#3 (Fig. 2D). There was an
increase over time post DC infusion not only in the frequency of
cytokine producing cells (upper panel), but also in the level of
cytokine each cell produce (lower graph). Remarkably, this
improvement occurred in all three cytokine categories, viz. the
IFNc single, TNFa single and TNFa/IFNc dual function, which
was not observed in the other patients. Interestingly, patient #3
received the highest DC dose (Fig. 2E). We also found that this
increase was mainly contributed by CD4+ T cell responses (Fig. 2F,
note the different scales for CD4 and CD8 T cells), supporting the
aim of the trial to enhance CD4+ T cell responses. While a similar
trend was not apparent in every patient, in PT#2 and PT#6 the
increase in TNFa single positive cells was quite remarkable
Figure 3. T cells expressing FOXP3. (A) Example of plots showing gate settings. (B) The frequency of FOXP3+ T cells at different time points,
gating on CD3+ T cells. (C) Inverse correlation between the frequencies of FOXP3+ Treg and CEF-specific TNFa/IFNc dual functional T cells.
doi:10.1371/journal.pone.0039368.g003
DC Immunotherapy in HCV Infection
PLOS ONE | www.plosone.org 5 August 2012 | Volume 7 | Issue 8 | e39368
(Fig. 2A). Although there may be some degree of non-specific
enhancement by Mo-DC infusion on cytokine production,
compared to the HCV-specific responses (Table S2), CEF-specific
responses were rather stable after DC vaccination, with the index
to baseline close to 1 (Table S3). Taken together, these data
suggest that a boost in HCV-specific T cell responses was likely
achieved by Mo-DC therapy in at least some patients, although
the overall pattern was consistent with our previous report [1] in
that the responses were sporadic, inconsistent among patients and
showed no apparent correlation with time or immunization dose/
route. We recognise that this Phase I trial had a small sample size
and consequently it was not feasible to apply a stringent cut-off for
positive responses. This has left potential biases introduced via
background subtraction unchecked. It would be valuable for these
results to be confirmed using a larger patient cohort and thus the
data should be considered with caution.
Both CD4+ and CD8+ T cells contributed to the positive
responses, however, since CD4+ cells were always more abundant
than CD8+ T cells, the net number of cytokine-producing CD4+ T
cells was usually greater than that of CD8+T cells (Figure S2A). The
cellular source of cytokines also included CD3+ but not typical
CD4+ or CD8+ T cells (Fig. 1C and Figure S2B), and the exact
nature of these cells was unclear. We noticed discrepancies between
our ICS data in this study and our previous ELISPOT data, and this
issue is addressed further in the supporting information (please see
Data S1), where we demonstrate, as well as discuss, that while not
fundamentally conflicting, ICS and ELISPOT were not quantita-
tively comparable. Consistent with the previous study we found that
positive cytokine responses were detected in response to viral
antigens that were not included in the cellular vaccine (for example
the response to NS2P7 in PT#6 and to NS5A in PT#3), suggesting
that Mo-DC therapy may induce broader responses via epitope
spreading [1] or other undefined mechanisms. RT-PCR amplifica-
tion of the circulating virus RNA followed by sequencing confirmed
that the peptides contained in the vaccine matched and thus
discrepancies between vaccine and virus did not account for the
poor immune responses [1]. We could not detect any IL2+ T cells,
other than after PMA/ionomycin stimulation in positive control
cultures (not shown), probably because the HCV peptide stimuli
were insufficient.
2. Mo-DC therapy in HCV patients may influence FOXP3+
Treg frequency
Recent work by us [8,10] and others (reviewed in [11]) suggested
that Treg may be implicated in HCV persistence and HCV-specific
Treg have been detected using tetramers [5,7,11,12]. We therefore
investigated the presence of Treg in patients in this trial. In each
patient the frequency of FOXP3+ Treg fluctuated at early time
points following DC infusions, but decreased to below baseline by
week 12 (Fig. 3, Table 2 and Table 3). If we compare values before
any DC infusion (baseline) and after the final infusion, there was a
statistically significant difference in the frequency of FOXP3+ Treg
(P= 0.013, Table 3). In particular, the week 12 median frequencies
tended to be lower than baseline values although not significant
when adjusted for multiple comparisons (1.385 to 1.09, P= 0.172,
Table 3, while before adjustment P= 0.043, data not shown). Due to
the small sample size, the power to detect any significant differences
is limited, but collectively, the frequency of Treg at week 12
displayed a trend of reduction compared to baseline, offering
exciting hints for future follow-up studies.
It has been reported that Mo-DC infusions induced FOXP3high
regulatory T cells, and depletion of CD25+ cells enhanced the
efficacy of Mo-DC-based immunotherapy in cancer patients
[12,13]. Our data suggest a different outcome, which can likely
be explained by a combination of differences in pathogenesis and
the design of the Mo-DC therapy. It is possible that this reduction
is temporary, within the time frame of the trial. We speculate that
the decrease in FOXP3 Treg is related to the increase in TNFa
single positive cells that showed a trend towards up-regulation
after the Mo-DC therapy. It was recently discovered that TNFa,
which signals through TNFRII expressed by Treg [14,15], is an
important regulator of Treg function in mice and humans, and
can variously promote or inhibit Treg activity in a dose-dependent
fashion [16,17]. It is therefore an intriguing possibility that
vaccine-induced HCV-specific and/or HCV-non-specific TNFa
production by effector T cells may temporarily reduce Treg
activity in these patients. We cannot exclude the possibility that
some FOXP3+ cells, especially during the early time points
following the initial infusion, may be in vivo activated conventional
T cells, as although FOXP3 is the best marker available for Treg it
is less specific in humans compared with mice [11,18]. However,
the frequency of FOXP3+ Treg was inversely correlated (P,0.001)
with that of CEF-specific responses (Fig. 3C), suggesting that the
FOXP3+ cells are principally Treg.
Collectively, these data suggested that our Mo-DC therapy was
capable of inducing multi-functional T cells, although there was no
consistent response related to either the timing, post DC infusion,
or the specific HCV antigen. The presence of Treg may however
complicate the in vivo immune response induced by the treatment.
Thus the phase I Mo-DC immunotherapy trial showed multiple
outcomes, but overall was unable to generate sustained cell-
mediated immune responses to break tolerance to HCV.
Alternative strategies to examine longer term therapy, different
antigens, vaccination routes, Treg manipulation or increased
dosage may need to be considered to achieve therapeutic benefit.
Table 2. The frequency (% within CD3+ T cells) of FOXP3+
Treg of the patients at various time points.
BL PI-2 PI-3 W2 W4 W6 W12
PT#1 1.35 1.47 1.83 1.14
PT#2 1.13 0.806 0.823 1.51 0.589 0.618
PT#3 1.91 1.53 1.73 2.25 1.87 1.71 1.83
PT#4 1.56 2.13 1.69 1.35 1.12 N/D
PT#5 1.31 0.753 1.4 1.22 1.1 1.06 1.09
PT#6 1.42 1.53 1.69 1.51 1.46 1.17 1
Mean 1.447 1.35 1.61 1.494 1.458 1.247 1.136
Median 1.385 1.53 1.69 1.49 1.46 1.145 1.09
SD 0.27 0.58 0.18 0.48 0.28 0.46 0.44
doi:10.1371/journal.pone.0039368.t002
Table 3. Skillings-Mack and Wilcoxon signed-rank test (with
Bonferroni adjustment) for FOXP3 data (see Table 2).
Comparison Test P-value
Baseline, Week 2, 4, 6, 12 only Skillings-Mack test 0.013*
BL vs wk12 Wilcoxon signed-ranks test 0.172
BL vs wk6 Wilcoxon signed-ranks test 0.992
BL vs wk4 Wilcoxon signed-ranks test 1.000
BL vs wk2 Wilcoxon signed-ranks test 1.000
doi:10.1371/journal.pone.0039368.t003
DC Immunotherapy in HCV Infection
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Supporting Information
Figure S1 The frequency of cytokine producing T cells
in the in vitro positive control CEF peptide pool
stimulated culture. All data were background subtracted using
the no antigen control. Analysis gated on viable CD3+ T cells.
(PDF)
Figure S2 Cytokine production by CD4 and/or CD8 T
cells. (A) Heat map depicting the frequency of cytokine producing
CD4+ and CD8+ T cells within viable (ViViD2) CD3+ T cells.
Data are background subtracted, and only positive values are
retained and coloured accordingly. (B) An example of positive
response (NS2P7 response in PT#6), depicting the cellular source
of the cytokines. The red dots represent cytokine+ T cells and the
grey dots are viable CD3+ T cell.
(PDF)
Table S1 Frequency (%) of cytokine producing T cells
within total viable CD3+ T cells, before background
subtraction.
(XLSX)
Table S2 Background subtracted data for HCV anti-
gens. A) Percentage of cytokine producing T cells within total
viable CD3+ T cells, background subtracted, and retaining positive
values only. B) Index to BL.
(XLSX)
Table S3 Background subtracted data for in vitro
positive control CEF. A) Percentage of cytokine producing T
cells within total viable CD3+ T cells, background subtracted, and
retaining positive values only. B) Index to BL for TNFa/IFNg
dual functional T cells.
(XLSX)
Data S1 Discrepancies between ELISpot and ICS data.
(PDF)
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